Yale Head and Neck SPORE Publications

2023

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1; 2022 Oct 11. PMID: 36219809.
Top advances of the year: Head and neck cancer.Verma A, Burtness B. Cancer. 2023 Jan 24; 2023 Jan 24. PMID: 36692372.
Author Correction: Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Nat Rev Dis Primers. 2023 Jan 19; 2023 Jan 19. PMID: 36658129.
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.Bhatia A, Burtness B. Drugs. 2023 Jan 16; 2023 Jan 16. PMID: 36645621.
The Pathologists' Conundrum.Rimm DL, Dacic S, Schnitt SJ. Arch Pathol Lab Med. 2023 Jan 1. PMID: 36577091.
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy.Rimm DL. JAMA Oncol. 2023 Jan 1. PMID: 36394848.

2022

Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. J Clin Oncol. 2022 Dec 20; 2022 Jul 22. PMID: 35867947.
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade.Vathiotis IA, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung TN, Shafi S, Wong PF, Jessel S, Kluger HM, Syrigos KN, Warren S, Gerstein M, Rimm DL. NPJ Precis Oncol. 2022 Dec 15; 2022 Dec 15. PMID: 36522538.
HIV is associated with poor overall survival among head and neck cancer patients.Salahuddin S, Cohen O, Wu M, Perez Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper KA, Mehra S, Yarbrough WG, Emu B. Clin Infect Dis. 2022 Dec 15; 2022 Dec 15. PMID: 36520995.
Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer.Wandrey NE, Gao D, Robin TP, Contessa JN, Singh C, Chiang V, Li J, Chen A, Wang Y, Sheehan JP, Dutta SW, Weiss SE, Paly J, Rusthoven CG. Lung Cancer. 2022 Dec 12; 2022 Dec 12. PMID: 36641932.
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. J Natl Cancer Inst. 2022 Dec 8. PMID: 36053203.
Methodologic Concerns in Secondary Analysis of KEYNOTE-048.Burtness B, Lin J, Souliéres D. JAMA Oncol. 2022 Dec 1. PMID: 36264563.
Outcomes Stratification of Head and Neck Cancer Using Pre- and Posttreatment DNA Methylation From Peripheral Blood.Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Stokes WA, Beitler JJ, Xiao C. Int J Radiat Oncol Biol Phys. 2022 Nov 21; 2022 Nov 21. PMID: 36410685.
Ki67 as a Companion Diagnostic: Good or Bad News?Dowsett M, Nielsen TO, Rimm DL, Hayes DF. J Clin Oncol. 2022 Nov 20; 2022 Jul 11. PMID: 35816627.
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. JCO Precis Oncol. 2022 Nov. PMID: 36446042.
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.Schoenfeld DA, Merkin RD, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm DL, Kluger HM. Front Oncol. 2022; 2022 Oct 13. PMID: 36313654.
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.Lalonde CS, Teng Y, Burtness BA, Ferris RL, Ahmed R, Saba NF. J Natl Cancer Inst. 2022 Oct 6. PMID: 35567531.
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, Lænkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Mod Pathol. 2022 Oct; 2022 Jun 21. PMID: 35729220.
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.Moutafi M, Robbins CJ, Yaghoobi V, Fernandez AI, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler DC, Fulton R, Rimm DL. Lab Invest. 2022 Oct; 2022 May 20. PMID: 35595825.
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Lab Invest. 2022 Oct; 2022 May 17. PMID: 35581307.
STING Agonists in Head and Neck Squamous Cell Carcinoma.Wallington DG, Contessa JN, Hayman TJ. Cancer J. 2022 Sep-Oct 01. PMID: 36165729.
Integrating Targeted Therapies in the Management of Head and Neck Cancers.Burtness B. Cancer J. 2022 Sep-Oct 01. PMID: 36165719.
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clin Cancer Res. 2022 Sep 1. PMID: 35903931.
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. J Thorac Oncol. 2022 Sep; 2022 Jun 25. PMID: 35764237.
Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Ophthalmic Plast Reconstr Surg. 2022 Sep-Oct 01; 2022 May 3. PMID: 35502804.
Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling.Vesely M, Martinez-Morilla S, Gehlhausen JR, McNiff JM, Whang PG, Rimm D, Ko CJ. J Am Acad Dermatol. 2022 Sep; 2022 Apr 6. PMID: 35398219.
Trends in Residency Applicant Volume in Otolaryngology-Head and Neck Surgery and Peer Specialties.Bourdillon AT, Salehi PP, Wride M, Salehi P, Torabi S, Heiser A, Shah HP, Azizzadeh B, Judson B, Lee YH. Ann Otol Rhinol Laryngol. 2022 Aug 29; 2022 Aug 29. PMID: 36031814.
The Effect of Tobacco Smoke N-Nitrosamines, NNK and NDEA, and Nicotine, on DNA Mismatch Repair Mechanism and miRNA Markers, in Hypopharyngeal Squamous Cell Carcinoma: An In Vivo Model and Clinical Evidence.Doukas SG, Vageli DP, Doukas PG, Nikitovic D, Tsatsakis A, Judson BL. Curr Oncol. 2022 Aug 4; 2022 Aug 4. PMID: 36005175.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. J Immunother Cancer. 2022 Aug. PMID: 36002182.
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. EBioMedicine. 2022 Aug; 2022 Jul 7. PMID: 35810563.
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2022 Aug; 2022 Apr 28. PMID: 35490853.
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.Forman R, Deshpande H, Burtness B, Bhatia AK. Head Neck. 2022 Aug; 2022 Apr 30. PMID: 35488876.
Major Salivary Gland Cancer With Distant Metastasis Upon Presentation: Patterns, Outcomes, and Imaging Implications.Benchetrit L, Mehra S, Mahajan A, Rahmati RW, Judson BL, Edwards HA. Otolaryngol Head Neck Surg. 2022 Aug; 2021 Nov 16. PMID: 34784258.
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. J Neurosurg. 2022 Jul 29; 2022 Jul 29. PMID: 35907197.
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2022 Jul 22; 2022 Jul 22. PMID: 35869114.
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. J Clin Oncol. 2022 Jul 20; 2022 Mar 25. PMID: 35333599.
The Role of PARP-1 and NF-κB in Bile-Induced DNA Damage and Oncogenic Profile in Hypopharyngeal Cells.Doukas PG, Vageli DP, Judson BL. Laryngoscope. 2022 Jul 6; 2022 Jul 6. PMID: 35791892.
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35793873.
Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy.Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR. Adv Radiat Oncol. 2022 Jul-Aug; 2022 Mar 21. PMID: 35521071.
Development of an immunohistochemical assay for Siglec-15.Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Lab Invest. 2022 Jul; 2022 Apr 22. PMID: 35459795.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Clin Cancer Res. 2022 Jun 13. PMID: 35377948.
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome.Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, Velu P, Leo P, Beig N, Li H, Toro P, Berezowska S, Baxi V, Balli D, Belete M, Rimm DL, Velcheti V, Schalper K, Madabhushi A. NPJ Precis Oncol. 2022 Jun 3; 2022 Jun 3. PMID: 35661148.
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.Lopez de Rodas M, Nagineni V, Ravi A, Datar IJ, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm DL, Herbst RS, Madabhushi A, Riess JW, Velcheti V, Hellmann MD, Gainor J, Schalper KA. J Immunother Cancer. 2022 Jun. PMID: 35649657.
Copy number variations identified in thyroid FNA specimens are associated with Hürthle cell cytomorphology.Abi-Raad R, Prasad ML, Adeniran AJ, Cai G. Cancer Cytopathol. 2022 Jun; 2022 Mar 25. PMID: 35332982.
NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.Schrank TP, Prince AC, Sathe T, Wang X, Liu X, Alzhanov DT, Burtness B, Baldwin AS, Yarbrough WG, Issaeva N. Oncotarget. 2022; 2022 May 24. PMID: 35634245.
Noxious Combination of Tobacco Smoke Nitrosamines with Bile, Deoxycholic Acid, Promotes Hypopharyngeal Squamous Cell Carcinoma, via NFκB, In Vivo.Vageli DP, Doukas PG, Doukas SG, Tsatsakis A, Judson BL. Cancer Prev Res (Phila). 2022 May 3. PMID: 35502554.
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.Deneka AY, Baca Y, Serebriiskii IG, Nicolas E, Parker MI, Nguyen TT, Xiu J, Korn WM, Demeure MJ, Wise-Draper T, Sukari A, Burtness B, Golemis EA. Clin Cancer Res. 2022 May 2. PMID: 35491653.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. J Immunother Cancer. 2022 May. PMID: 35640927.
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Oral Oncol. 2022 May; 2022 Apr 2. PMID: 35381576.
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Future Oncol. 2022 May; 2022 Feb 17. PMID: 35172587.
Aberrant Cellular Glycosylation May Increase the Ability of Influenza Viruses to Escape Host Immune Responses through Modification of the Viral Glycome.Alymova IV, Cipollo JF, Parsons LM, Music N, Kamal RP, Tzeng WP, Goldsmith CS, Contessa JN, Hartshorn KL, Wilson JR, Zeng H, Gansebom S, York IA. mBio. 2022 Apr 26; 2022 Mar 14. PMID: 35285699.
Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies.Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Stat Med. 2022 Apr 15; 2021 Dec 12. PMID: 34897773.
Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.Wise-Draper TM, Bahig H, Tonneau M, Karivedu V, Burtness B. Am Soc Clin Oncol Educ Book. 2022 Apr. PMID: 35486888.
Inhibition of renalase drives tumour rejection by promoting T cell activation.Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Eur J Cancer. 2022 Apr; 2022 Feb 24. PMID: 35219026.
Reply to A.S. Garden.Ferris RL, Burtness B, Flamand Y. J Clin Oncol. 2022 Apr 1; 2022 Feb 16. PMID: 35171688.
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. JAMA Oncol. 2022 Apr 1. PMID: 35113160.
RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.Gilani SM, Abi-Raad R, Garritano J, Cai G, Prasad ML, Adeniran AJ. Cancer Cytopathol. 2022 Apr; 2021 Nov 30. PMID: 34847284.
Anaplastic Thyroid Carcinoma: Cytomorphologic Features on Fine-Needle Aspiration and Associated Diagnostic Challenges.Podany P, Abi-Raad R, Barbieri A, Garritano J, Prasad ML, Cai G, Adeniran AJ, Gilani SM. Am J Clin Pathol. 2022 Apr 1. PMID: 34661606.
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.Dieli-Conwright CM, Harrigan M, Cartmel B, Chagpar A, Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. NPJ Breast Cancer. 2022 Mar 7; 2022 Mar 7. PMID: 35256599.
Standardization of PD-L1 immunohistochemistry.Martinez-Morilla S, Moutafi M, Rimm DL. Mod Pathol. 2022 Mar; 2021 Sep 10. PMID: 34508229.
Assessing Human Papillomavirus Awareness and the Role of Oropharyngeal Squamous Cell Carcinoma Education on Improving Intention to Vaccinate.Torabi SJ, Su-Velez BM, Kasle DA, Yarbrough WG, St John M, Judson BL. Laryngoscope. 2022 Mar; 2021 Aug 12. PMID: 34383306.
Resident Burnout and Well-being in Otolaryngology and Other Surgical Specialties: Strategies for Change.Shah HP, Salehi PP, Ihnat J, Kim DD, Salehi P, Judson BL, Azizzadeh B, Lee YH. Otolaryngol Head Neck Surg. 2022 Feb 8; 2022 Feb 8. PMID: 35133919.
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. NPJ Breast Cancer. 2022 Feb 3; 2022 Feb 3. PMID: 35115541.
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. Sci Transl Med. 2022 Feb 2; 2022 Feb 2. PMID: 35108062.
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. J Immunother Cancer. 2022 Feb. PMID: 35217573.
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M Jr, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR Jr, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Eur J Cancer. 2022 Feb; 2021 Dec 31. PMID: 34980502.
Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.Cohen O, Brauer PR, Judson BL, Burtness BA, Earles J, Mehra S. Oral Oncol. 2022 Feb; 2021 Dec 28. PMID: 34971883.
Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV. J Am Soc Nephrol. 2022 Feb; 2021 Dec 17. PMID: 34921111.
Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Cancer Lett. 2022 Feb 1; 2021 Nov 12. PMID: 34780851.
A 2020 Update on Public Awareness of Head and Neck Cancers.Torabi SJ, Kasle DA, Su-Velez BM, Mehra S, Day TA, Yarbrough WG, St John M, Judson BL. Otolaryngol Head Neck Surg. 2022 Feb; 2021 Apr 13. PMID: 33845657.
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.Gavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung TN, Shafi S, Fernandez A, Schalper K, Psyrri A, Rimm DL. Clin Cancer Res. 2022 Jan 15; 2021 Oct 22. PMID: 34686497.
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. J Clin Oncol. 2022 Jan 10; 2021 Oct 26. PMID: 34699271.
PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma.Hong CS, Khan M, Sukys JM, Prasad M, Erson-Omay EZ, Vining EM, Omay SB. Cold Spring Harb Mol Case Stud. 2022 Jan; 2022 Jan 10. PMID: 34667073.
The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients.Trant AA, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. Integr Cancer Ther. 2022 Jan-Dec. PMID: 36444764.
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. Cancer Med. 2022 Jan; 2021 Dec 17. PMID: 34921525.
Targeting STAT3 prevents bile reflux-induced oncogenic molecular events linked to hypopharyngeal carcinogenesis.Vageli DP, Doukas PG, Siametis A, Judson BL. J Cell Mol Med. 2022 Jan; 2021 Dec 1. PMID: 34850540.
Artificial intelligence applied to breast pathology.Yousif M, van Diest PJ, Laurinavicius A, Rimm D, van der Laak J, Madabhushi A, Schnitt S, Pantanowitz L. Virchows Arch. 2022 Jan; 2021 Nov 18. PMID: 34791536.
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer.Farahmand S, Fernandez AI, Ahmed FS, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. Mod Pathol. 2022 Jan; 2021 Sep 7. PMID: 34493825.

2021

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Breast Cancer Res. 2021 Dec 14; 2021 Dec 14. PMID: 34906209.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. NPJ Breast Cancer. 2021 Dec 1; 2021 Dec 1. PMID: 34853355.
Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.Doroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL. J Thorac Oncol. 2021 Dec; 2021 Aug 26. PMID: 34455068.
PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.Gavrielatou N, Shafi S, Gaule P, Rimm DL. J Natl Cancer Inst. 2021 Nov 29. PMID: 34097056.
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.Zerdes I, Simonetti M, Matikas A, Harbers L, Acs B, Boyaci C, Zhang N, Salgkamis D, Agartz S, Moreno-Ruiz P, Bai Y, Rimm DL, Hartman J, Mezheyeuski A, Bergh J, Crosetto N, Foukakis T. NPJ Breast Cancer. 2021 Nov 19; 2021 Nov 19. PMID: 34799582.
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Clin Cancer Res. 2021 Nov 15; 2021 Aug 31. PMID: 34465600.
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer.MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Cancers (Basel). 2021 Nov 2; 2021 Nov 2. PMID: 34771664.
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Neuro Oncol. 2021 Nov 2. PMID: 33914067.
Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.Yu J, Tsay C, Sasaki C, Son YH, Decker RH, Mehra S, Burtness B. Oral Oncol. 2021 Nov; 2021 Oct 20. PMID: 34688055.
Bile reflux and hypopharyngeal cancer (Review).Vageli DP, Doukas SG, Doukas PG, Judson BL. Oncol Rep. 2021 Nov; 2021 Sep 24. PMID: 34558652.
An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Nimeus E, Hartman J, Acs B, Rimm DL. Clin Cancer Res. 2021 Oct 15; 2021 Jun 4. PMID: 34088723.
Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale.Morrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Acad Pathol. 2021 Jan-Dec; 2021 Oct 7. PMID: 34646939.
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.Lu BY, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, Chiang VL, Contessa JN, Adeniran AJ, Jilaveanu LB, Kluger HM, Schalper KA, Goldberg SB. J Immunother Cancer. 2021 Oct. PMID: 34670827.
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.Van Bockstal MR, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, Kooreman L, van der Vegt B, Verhoog L, Vreuls C, Westenend P, Kok M, van Diest PJ, Nauwelaers I, Laudus N, Denkert C, Rimm D, Siziopikou KP, Ely S, Zardavas D, Roberts M, Floris G, Hartman J, Acs B, Peeters D, Bartlett JMS, Dequeker E, Salgado R, Giudici F, Michiels S, Horlings H, van Deurzen CHM. Cancers (Basel). 2021 Sep 29; 2021 Sep 29. PMID: 34638394.
Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.Xiao C, Beitler JJ, Peng G, Levine ME, Conneely KN, Zhao H, Felger JC, Wommack EC, Chico CE, Jeon S, Higgins KA, Shin DM, Saba NF, Burtness BA, Bruner DW, Miller AH. Cancer. 2021 Sep 15; 2021 May 24. PMID: 34027995.
Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas.Jin L, Youngblood MW, Gupte TP, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera SM, Mishra-Gorur K, Blondin NA, Gorelick E, Omay SB, Pointdujour-Lim R, Judson BL, Alperovich M, Aboian MS, McGuone D, Gunel M, Erson-Omay Z, Fulbright RK, Moliterno J. J Neurooncol. 2021 Sep; 2021 Aug 4. PMID: 34350560.
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer.Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Int J Radiat Oncol Biol Phys. 2021 Sep 1; 2021 Apr 18. PMID: 33882281.
Anesthesia screen use may impact operating room communication practices in otolaryngology.Bourdillon AT, Mehra S, Rahmati R, Judson B, Edwards HA. Am J Otolaryngol. 2021 Sep-Oct; 2021 Mar 22. PMID: 33812208.
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis.Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. Front Oncol. 2021; 2021 Aug 30. PMID: 34527580.
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. J Clin Oncol. 2021 Aug 20; 2021 May 27. PMID: 34043410.
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.Apostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Cancer Res. 2021 Aug 15; 2021 Jun 21. PMID: 34185676.
An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy.Perincheri S, Levi AW, Celli R, Gershkovich P, Rimm D, Morrow JS, Rothrock B, Raciti P, Klimstra D, Sinard J. Mod Pathol. 2021 Aug; 2021 Mar 29. PMID: 33782551.